MX2020001235A - Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. - Google Patents
Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.Info
- Publication number
- MX2020001235A MX2020001235A MX2020001235A MX2020001235A MX2020001235A MX 2020001235 A MX2020001235 A MX 2020001235A MX 2020001235 A MX2020001235 A MX 2020001235A MX 2020001235 A MX2020001235 A MX 2020001235A MX 2020001235 A MX2020001235 A MX 2020001235A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrazolo
- pyrimidin
- dihydro
- analogs
- compounds
- Prior art date
Links
- JTNQNHQPENYUGB-UHFFFAOYSA-N 1,2-dihydropyrazolo[3,4-d]pyrimidin-3-one Chemical class C1=NC=C2C(O)=NNC2=N1 JTNQNHQPENYUGB-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539734P | 2017-08-01 | 2017-08-01 | |
| PCT/US2018/044580 WO2019028008A1 (en) | 2017-08-01 | 2018-07-31 | 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020001235A true MX2020001235A (es) | 2020-07-20 |
Family
ID=65233095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001235A MX2020001235A (es) | 2017-08-01 | 2018-07-31 | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11124518B2 (https=) |
| EP (1) | EP3661918B1 (https=) |
| JP (1) | JP7203816B2 (https=) |
| KR (1) | KR20200034781A (https=) |
| CN (1) | CN111094253B (https=) |
| AR (1) | AR112774A1 (https=) |
| AU (1) | AU2018312448B2 (https=) |
| BR (1) | BR112020002104A2 (https=) |
| CA (1) | CA3071405A1 (https=) |
| ES (1) | ES2980537T3 (https=) |
| IL (1) | IL272262A (https=) |
| MX (1) | MX2020001235A (https=) |
| RU (1) | RU2020105058A (https=) |
| SG (1) | SG11202000789WA (https=) |
| TW (1) | TW201910335A (https=) |
| WO (1) | WO2019028008A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019074979A1 (en) | 2017-10-09 | 2019-04-18 | Girafpharma, Llc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| US10807994B2 (en) | 2017-10-09 | 2020-10-20 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| EP3758706A4 (en) * | 2018-02-28 | 2021-11-24 | The Regents Of The University Of Colorado | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THEREOF |
| MX2020009372A (es) * | 2018-03-09 | 2020-10-14 | Recurium Ip Holdings Llc | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. |
| CN110872296B (zh) * | 2018-08-31 | 2023-05-23 | 上海弘翊生物科技有限公司 | 一种二氢异吲哚-1H-吡唑并[3,4-d]嘧啶酮化合物、其制备方法和应用 |
| CN113939296A (zh) * | 2019-04-09 | 2022-01-14 | 诺维逊生物股份有限公司 | 杂环化合物及其用途 |
| US20220220115A1 (en) * | 2019-04-09 | 2022-07-14 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| WO2020210381A1 (en) * | 2019-04-09 | 2020-10-15 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| WO2020210320A1 (en) * | 2019-04-11 | 2020-10-15 | Recurium Ip Holdings, Llc | Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| CN112142748B (zh) * | 2019-06-28 | 2023-07-04 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| KR20220042127A (ko) | 2019-06-28 | 2022-04-04 | 상하이 파마슈티컬스 홀딩 컴퍼니 리미티드 | 피라졸로피리미딘 화합물, 그의 제조 방법 및 그의 응용 |
| CN112442049A (zh) * | 2019-09-03 | 2021-03-05 | 微境生物医药科技(上海)有限公司 | 作为Wee1抑制剂的嘧啶衍生物 |
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| AU2020407070A1 (en) * | 2019-12-20 | 2022-07-14 | Recurium Ip Holdings, Llc | Combinations |
| AU2021271844A1 (en) * | 2020-05-15 | 2022-12-08 | Recurium Ip Holdings, Llc | Mono- and combination therapies |
| US12522607B2 (en) | 2020-06-17 | 2026-01-13 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Substituted pyrazolo[3,4-d]pyrimidines as wee-1 inhibitors |
| BR112023000350A2 (pt) | 2020-07-09 | 2023-03-28 | Recurium Ip Holdings Llc | Sais e formas de um inibidor de wee1 |
| CN114805357B (zh) * | 2021-01-21 | 2023-12-19 | 四川大学 | 一种靶向setdb1-ttd的小分子抑制剂及其制药用途 |
| AU2022265032A1 (en) * | 2021-04-30 | 2023-11-16 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof |
| AU2022287033B2 (en) * | 2021-06-04 | 2025-04-17 | Aprea Therapeutics, Inc. | Pyridopyrimidine derivatives useful as wee1 kinase inhibitors |
| WO2023016417A1 (zh) * | 2021-08-11 | 2023-02-16 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物 |
| WO2023045942A1 (zh) * | 2021-09-22 | 2023-03-30 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物 |
| WO2023166080A1 (en) | 2022-03-01 | 2023-09-07 | Step Pharma S.A.S. | Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1846408B1 (en) | 2005-01-14 | 2013-03-20 | Janssen Pharmaceutica NV | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| AR060635A1 (es) * | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
| EP2213673B1 (en) * | 2007-10-23 | 2013-06-05 | Msd K.K. | Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
| ME03455B (me) * | 2012-09-10 | 2020-01-20 | Principia Biopharma Inc | Jedinjenja pirazolopirimidina kao inhibitori kinaze |
| GB201612092D0 (en) | 2016-07-12 | 2016-08-24 | Almac Discovery Ltd | Pharmaceutical compounds |
-
2018
- 2018-07-31 CA CA3071405A patent/CA3071405A1/en active Pending
- 2018-07-31 AU AU2018312448A patent/AU2018312448B2/en not_active Ceased
- 2018-07-31 WO PCT/US2018/044580 patent/WO2019028008A1/en not_active Ceased
- 2018-07-31 RU RU2020105058A patent/RU2020105058A/ru unknown
- 2018-07-31 SG SG11202000789WA patent/SG11202000789WA/en unknown
- 2018-07-31 EP EP18842344.6A patent/EP3661918B1/en active Active
- 2018-07-31 MX MX2020001235A patent/MX2020001235A/es unknown
- 2018-07-31 TW TW107126578A patent/TW201910335A/zh unknown
- 2018-07-31 JP JP2020505356A patent/JP7203816B2/ja active Active
- 2018-07-31 CN CN201880059242.4A patent/CN111094253B/zh active Active
- 2018-07-31 US US16/635,348 patent/US11124518B2/en active Active
- 2018-07-31 ES ES18842344T patent/ES2980537T3/es active Active
- 2018-07-31 KR KR1020207005636A patent/KR20200034781A/ko not_active Ceased
- 2018-07-31 BR BR112020002104-0A patent/BR112020002104A2/pt not_active Application Discontinuation
- 2018-08-01 AR ARP180102185A patent/AR112774A1/es not_active Application Discontinuation
-
2020
- 2020-01-26 IL IL272262A patent/IL272262A/en unknown
-
2021
- 2021-06-15 US US17/304,154 patent/US20210317124A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3661918A4 (en) | 2021-05-12 |
| AU2018312448B2 (en) | 2022-09-15 |
| KR20200034781A (ko) | 2020-03-31 |
| BR112020002104A2 (pt) | 2020-08-04 |
| CN111094253B (zh) | 2023-08-29 |
| ES2980537T3 (es) | 2024-10-01 |
| US20200157112A1 (en) | 2020-05-21 |
| US20210317124A1 (en) | 2021-10-14 |
| EP3661918A1 (en) | 2020-06-10 |
| SG11202000789WA (en) | 2020-02-27 |
| RU2020105058A (ru) | 2021-09-02 |
| EP3661918B1 (en) | 2024-05-08 |
| AU2018312448A1 (en) | 2020-02-13 |
| RU2020105058A3 (https=) | 2021-11-17 |
| IL272262A (en) | 2020-03-31 |
| CA3071405A1 (en) | 2019-02-07 |
| AR112774A1 (es) | 2019-12-11 |
| US11124518B2 (en) | 2021-09-21 |
| CN111094253A (zh) | 2020-05-01 |
| WO2019028008A1 (en) | 2019-02-07 |
| JP7203816B2 (ja) | 2023-01-13 |
| EP3661918C0 (en) | 2024-05-08 |
| TW201910335A (zh) | 2019-03-16 |
| JP2020529993A (ja) | 2020-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023010806A (es) | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. | |
| MX2020001235A (es) | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. | |
| MX2023009185A (es) | Compuestos de benzamida. | |
| MX2023000410A (es) | Analogos de rapamicina como inhibidores de mtor. | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| WO2020210320A8 (en) | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones | |
| PH12020551305A1 (en) | Pharmaceutical Compounds | |
| MX2023011282A (es) | Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor. | |
| MX2022005780A (es) | Moduladores de receptores estrogenicos. | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| EP4365179A3 (en) | Novel rapamycin derivatives | |
| MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
| JOP20200315A1 (ar) | مركبات بورينون واستخدامها في معالجة السرطان | |
| PH12019500480A1 (en) | Pyridine compound | |
| PH12017501061A1 (en) | 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| NZ735648A (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| PH12020551343A1 (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer | |
| PH12022550497A1 (en) | Perk inhibiting compounds | |
| MX379704B (es) | Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida | |
| PH12021552953A1 (en) | Tricyclic compounds |